Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG
Zoran Rankovic1, Jiaqiang Cai, Jennifer Kerr
1Merck Research Laboratories, MSD, Newhouse, Lanarkshire, ML1 5SH Scotland, United Kingdom. zoran.rankovic@merck.com
Bioorganic & Medicinal Chemistry Letters
|September 17, 2010
Abstract:
Several structure-guided optimisation strategies were explored in order to improve the hERG selectivity profile of cathepsin K inhibitor 1, whilst maintaining its otherwise excellent in vitro and in vivo profile. Ultimately, attenuation of clogP and pK(a) properties proved a successful approach and led to the discovery of a potent analogue 23, which, in addition to the desired selectivity over hERG (>1000-fold), displayed a highly attractive overall profile.


